Head and neck cancer immunotherapy research study
Part of Cancer clinical trials.
This study is looking for people with advanced head and neck cancer who have already received immunotherapy plus chemotherapy as their first treatment. Researchers will study your tumor tissue and proteins to find better ways to use immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of head and neck cancer (squamous cell carcinoma) that has come back or spread to other parts of the body.
- Your first treatment for advanced cancer included both an immunotherapy drug and chemotherapy.
- A sample of your tumor is already stored at Samsung Medical Center.
- Your doctors have checked the levels of certain proteins (p16 and PD-L1) on your tumor.
- You are 20 years or older and can understand and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial collects tissue and health information to find the best treatment for your head and neck cancer. It may help guide your care by looking at the genetic details of your tumor.
This study focuses on testing a personalized immune therapy (made from your tumor-fighting T cells) for people with head and neck cancer. It may help patients whose cancer is new and untreated or whose cancer has come back or is not responding to standard options.
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial tests a combination of an immunotherapy drug (toripalimab) and two chemotherapy drugs (cisplatin and docetaxel) as a first treatment before surgery or radiation for advanced head and neck cancers. It may help shrink tumors that can't be easily treated with standard therapy.
This trial studies the role of epigenetic marks in head and neck cancer to improve diagnosis and treatment. If you have been newly diagnosed with head and neck squamous cell carcinoma and have not yet received treatment, you may be eligible to participate.
This Phase 2 study looks at what treatment is best after you first receive chemotherapy plus immunotherapy, then have surgery for head and neck squamous cell cancer. It tries to use how your tumor responds (shown in lab tissue after treatment) to guide the next steps, which may improve outcomes.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.